358 related articles for article (PubMed ID: 37224925)
21. A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
Li X; Lu Y; Liang X; Zhou X; Li D; Zhang Z; Niu Y; Liu S; Ye L; Zhang R
PLoS One; 2023; 18(5):e0286257. PubMed ID: 37228085
[TBL] [Abstract][Full Text] [Related]
22. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
[TBL] [Abstract][Full Text] [Related]
23. Myeloid-specific deletion of chitinase-3-like 1 protein ameliorates murine diet-induced steatohepatitis progression.
Kim AD; Kui L; Kaufmann B; Kim SE; Leszczynska A; Feldstein AE
J Mol Med (Berl); 2023 Jul; 101(7):813-828. PubMed ID: 37166517
[TBL] [Abstract][Full Text] [Related]
24. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.
Tsuchida T; Lee YA; Fujiwara N; Ybanez M; Allen B; Martins S; Fiel MI; Goossens N; Chou HI; Hoshida Y; Friedman SL
J Hepatol; 2018 Aug; 69(2):385-395. PubMed ID: 29572095
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
26. A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis.
Hammoutene A; Biquard L; Lasselin J; Kheloufi M; Tanguy M; Vion AC; Mérian J; Colnot N; Loyer X; Tedgui A; Codogno P; Lotersztajn S; Paradis V; Boulanger CM; Rautou PE
J Hepatol; 2020 Mar; 72(3):528-538. PubMed ID: 31726115
[TBL] [Abstract][Full Text] [Related]
27. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
28. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.
Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA
Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212
[TBL] [Abstract][Full Text] [Related]
29. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
30. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Suzuki-Kemuriyama N; Abe A; Nakane S; Yuki M; Miyajima K; Nakae D
PLoS One; 2023; 18(8):e0287657. PubMed ID: 37535625
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models.
Gwag T; Ma E; Zhou C; Wang S
Liver Int; 2022 Apr; 42(4):829-841. PubMed ID: 35129307
[TBL] [Abstract][Full Text] [Related]
33. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
[TBL] [Abstract][Full Text] [Related]
34. miR-21-5p promotes NASH-related hepatocarcinogenesis.
Rodrigues PM; Afonso MB; Simão AL; Islam T; Gaspar MM; O'Rourke CJ; Lewinska M; Andersen JB; Arretxe E; Alonso C; Santos-Laso Á; Izquierdo-Sanchez L; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Prip-Buus C; Banales JM; Rodrigues CMP; Castro RE
Liver Int; 2023 Oct; 43(10):2256-2274. PubMed ID: 37534739
[TBL] [Abstract][Full Text] [Related]
35. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.
Asgharpour A; Cazanave SC; Pacana T; Seneshaw M; Vincent R; Banini BA; Kumar DP; Daita K; Min HK; Mirshahi F; Bedossa P; Sun X; Hoshida Y; Koduru SV; Contaifer D; Warncke UO; Wijesinghe DS; Sanyal AJ
J Hepatol; 2016 Sep; 65(3):579-88. PubMed ID: 27261415
[TBL] [Abstract][Full Text] [Related]
36. Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis.
Mohammed S; Thadathil N; Ohene-Marfo P; Tran AL; Van Der Veldt M; Georgescu C; Oh S; Nicklas EH; Wang D; Haritha NH; Luo W; Janknecht R; Miller BF; Wren JD; Freeman WM; Deepa SS
Mol Cancer Res; 2023 Sep; 21(9):933-946. PubMed ID: 37204757
[TBL] [Abstract][Full Text] [Related]
37. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.
Nardo AD; Grün NG; Zeyda M; Dumanic M; Oberhuber G; Rivelles E; Helbich TH; Markgraf DF; Roden M; Claudel T; Trauner M; Stulnig TM
Liver Int; 2020 Jul; 40(7):1620-1633. PubMed ID: 32281248
[TBL] [Abstract][Full Text] [Related]
38. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
39. A Mouse Model of Hepatocellular Carcinoma Induced by Streptozotocin and High-Fat Diet.
Motiño O; Li S; Lambertucci F; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Chen H; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():67-75. PubMed ID: 38315389
[TBL] [Abstract][Full Text] [Related]
40. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.
Kim ER; Park JS; Kim JH; Oh JY; Oh IJ; Choi DH; Lee YS; Park IS; Kim S; Lee DH; Cheon JH; Bae JW; Lee M; Cho JW; An IB; Nam EJ; Yang SI; Lee MS; Bae SH; Lee YH
Hepatology; 2022 Jun; 75(6):1523-1538. PubMed ID: 34773257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
